Implementation and Evaluation of a Complex Intervention to Reduce Avoidable Transitions Between Nursing Home and Hospital
Condition(s) studied
Investigational drug(s) / intervention(s)
RATHER-NH Toolkit: A) Stop and Watch Early Warning Tool B) Decision trees C) General Practitioner communication tool
Study summary
Hospital admissions can have a negative impact on the physical and emotional health of nursing home residents. Although evidence-based interventions have been developed to reduce hospitalisations, the evidence regarding their effectiveness is inconclusive and challenges have been reported in implementing these interventions within the nursing home context. Hence, this study aimed to implement and evaluate a complex intervention to reduce avoidable transitions between nursing home and hospital (RATHER-NH).
Eligibility
Primary outcome measure(s)
- Outcomes on healthcare use per 100 person-months — Retrospective baseline measurement of 3 months, during the intervention (period of 9 months) untill 3 months post-intervention for the post-interventions measurement.
Rate of hospitalisations per 100 person-months, rate of out-of-hours GP contacts per 100 person-months, rate of emergency department visits (without hospitalisation) per 100 person-months. - Outcomes on healthcare use per hospitalisation — Retrospective baseline measurement of 3 months, during the intervention (period of 9 months) untill 3 months post-intervention for the post-interventions measurement.
Length of hospital stay, cause of hospitalisation, hospitalisation in the last month of life (in case of death) and place of death
Trial sites (6)
| Facility | City | Region | Status |
|---|---|---|---|
| WZC De Cocon | Dendermonde | Belgium | |
| WZC Sint-Elisabeth | Eeklo | Belgium | |
| WZC Domino | Ghent | Belgium | |
| WZC Annuntiaten | Heverlee | Belgium | |
| WZC Ter Moere | Lokeren | Belgium | |
| WZC Martinas | Merchtem | Belgium |
More Vrije Universiteit Brussel trials in Belgium
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07359521 on ClinicalTrials.gov ↗ ← All trials in Belgium